Case number | Gender | Age at diagnosis | Tumour localisation | Laurén phenotype | T-category | N-category | M-category | UICC stage | Tumour grade | KRAS codon 12 and 13 | PIK3CA exon 9 | PIK3CA exon 20 | MSI status | EBV status | Helicobacter pylori status | RHOA mutation | RHOA exon | RHOA substitution mutation | Functional region—interaction with | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | F | 44 | Distal | Diffuse | T1b | N0 | M0 | IA | G2 | WT | WT | WT | MSS | − | mv | c.125A>G, p.Y42C | 2 | Transition | Effector domain | |
2 | F | 38 | Distal | Diffuse | T3 | N1 | M0 | IIIA | G3 | WT | WT | WT | MSS | − | − | c.169T>G, p.L57V | 3 | Transversion | PKN/PRK1 | |
3 | F | 66 | Distal | Diffuse | T1a | N0 | M0 | IA | G3 | WT | WT | WT | MSS | − | − | c.169T>G, p.L57V | 3 | Transversion | PKN/PRK1 | |
4 | F | 80 | Distal | Diffuse | T4a | N2 | M0 | IIIB | G3 | WT | WT | WT | MSS | − | − | c.65_66delinsGT, p.L22R | 2 | Deletion/Insertion | – | |
5 | F | 68 | Distal | Diffuse | T4a | N3a | M0 | IIIC | G3 | WT | WT | WT | MSS | − | mv | c.206T>G, p.L69R# | 3 | Transversion | – | |
6 | F | 69 | Proximal | Diffuse | T2 | N0 | M0 | IB | G3 | WT | WT | WT | MSS | − | − | c.125A>G, p.Y42C | 2 | Transition | Effector domain | |
7 | M | 90 | Proximal | Diffuse | T3 | N3 | M0 | IIIB | G3 | WT | WT | WT | MSS | − | − | c.50G>A, p.G17E | 2 | Transition | GTP | |
8 | M | 68 | Proximal | Diffuse | T3 | N2 | M0 | IIIA | G3 | WT | WT | WT | MSS | − | − | c.14G>A, p.R5Q | 2 | Transition | – | |
9 | M | 62 | Distal | Diffuse | T3 | N2 | M0 | IIIA | G3 | WT | WT | WT | MSS | − | mv | c.109A>G, p.T37A# | 2 | Transition | Effector domain | |
10 | F | 72 | Distal | Intestinal | T3 | N3a | M0 | IIIB | G3 | WT | WT | WT | MSS | − | − | c.125A>G, p.Y42C | 2 | Transition | Effector domain | |
11 | M | 84 | Distal | Intestinal | T2 | N0 | M0 | IB | G3 | WT | WT | WT | MSS | − | − | c.125A>G, p.Y42C | 2 | Transition | Effector domain | |
12 | M | 85 | Distal | Intestinal | T2 | N3a | M0 | IIIA | G3 | WT | WT | WT | MSS | − | − | c.70G>T, p.V24F | 2 | Transversion | – | |
13 | M | 66 | Distal | Intestinal | T3 | N0 | M0 | IIA | G3 | WT | WT | WT | MSI | − | + | c.50delinsAA, p.G17Efs*24# | 2 | Deletion/Insertion | GTP | |
14 | F | 80 | Distal | Unclassified | T3 | N1 | M0 | IIB | G3 | WT | WT | WT | MSS | − | − | c.169T>G, p.L57V | 3 | Transversion | PKN/PRK1 | |
15 | F | 58 | Distal | Unclassified | T1b | N3b | M0 | IIB | G3 | WT | WT | WT | MSS | − | − | c.125A>G, p.Y42C | 2 | Transition | Effector domain | |
16 | M | 59 | Distal | Mixed | T4b | N3a | M0 | IIIC | G3 | WT | MUT | WT | MSS | + | + | c.14G>A, p.R5Q | 2 | Transition | – |
#, hitherto unreported mutations; −, negative; +, positive; EBV, Epstein–Barr virus; GTP, guanosine triphosphate; MSI, microsatellite instable; MSS, microsatellite stable; mv, missing value; PKN/PRK1, protein kinase N1; UICC, Union for International Cancer Control; WT, wildtype.